Please Wait.....
Report
Liquid Biopsy Market - Global Outlook & Forecast 2023-2028
Market Report I 2023-10-11 I 377 Pages I Arizton Advisory & Intelligence
The global liquid biopsy market is expected to grow at a CAGR of 23.19% from 2022-2028.
MARKET TRENDS & DRIVERS
Increasing Role of Liquid Biopsy as a Companion Diagnostics
As liquid biopsy technologies continue to advance, their role as companion diagnostics is expanding rapidly. The non-invasive nature, ability to capture tumor heterogeneity and dynamics, early detection of MRD, real-time treatment response assessment, targeted therapy selection, and biomarker discovery make liquid biopsy an invaluable tool in guiding personalized treatment strategies. The integration of liquid biopsy as a companion diagnostic is transforming the field of precision medicine, leading to more effective and tailored therapeutic approaches for patients.
New Product Launches
The liquid biopsy market has witnessed several notable product launches in recent years. Companies like Guardant Health, Roche, and Illumina have introduced innovative solutions to enhance liquid biopsy capabilities. These include new liquid biopsy assays with expanded gene panels, improved sensitivity, and increased accuracy. Advanced platforms and technologies, such as digital PCR and next-generation sequencing (NGS), have also been introduced to enable more comprehensive and precise analysis of circulating biomarkers. Bioinformatics tools and software have also been developed to facilitate data analysis and interpretation, enhancing the clinical utility of liquid biopsy.
Higher Patient Preference for Non-invasive Diagnosis and Monitoring
The preference for non-invasive diagnosis and monitoring methods has become a significant driver for the liquid biopsy industry. Patients and healthcare providers increasingly recognize the advantages of liquid biopsy over invasive tissue biopsies, such as reduced procedural risks, minimal discomfort, and the ability to obtain multiple samples over time. Liquid biopsy's non-invasive nature also allows for easier accessibility, especially in cases where obtaining tissue biopsies may be challenging or impractical. The growing demand for non-invasive diagnostic approaches aligns with the convenience, safety, and potential for real-time monitoring offered by liquid biopsy, contributing to its expanding adoption and market growth.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT
The kits & reagents product segment dominated the global liquid biopsy market and is projected to witness the fastest growth rate of over 23% during the forecast period. Liquid biopsy kits and reagents are tools used to detect and diagnose cancer. Liquid biopsy kits and reagents are designed to detect and analyze specific biomarkers in the blood, urine, saliva, or other bodily fluids. Different reagents may be used to identify and measure the biomarkers depending on the type of liquid sample used. Overall, liquid biopsy kits and reagents have revolutionized the field of cancer detection and diagnosis. With these tools, clinicians can now detect and diagnose cancer more accurately, quickly, and cost-effectively than ever before.
Segmentation by Product
- Kits & Reagents
- Instruments & Platforms
INSIGHTS BY SAMPLE TYPE
The global liquid biopsy market by sample type segments as blood and others. The blood segment held the largest global market share. The development of liquid biopsy has revolutionized medical diagnostics and changed how we approach disease treatment. Liquid biopsy is a type of biopsy procedure involving the extraction of genetic material from a patient's blood or other bodily fluid for disease diagnosis and prognosis. One of the most common and widely used liquid biopsy methods is the analysis of blood samples.
Segmentation by Sample Type
- Blood
- Others
INSIGHTS BY APPLICATION
The global liquid biopsy market by application segments by cancer and non-cancer.The cancer segment accounted for the largest global liquid biopsy market share. Cancer is a major health concern, and its early detection is critical for successful treatment. Unfortunately, traditional invasive biopsies are often painful, expensive, and not always suitable for cancer detection. As a result, liquid biopsy has emerged as an attractive alternative, offering the potential to detect cancer earlier and with less risk. A liquid biopsy is a minimally invasive procedure that analyzes molecules in body fluids such as blood or urine to detect cancer. By analyzing cancer-specific molecules, such as circulating tumor DNA, commonly known as ctDNA, or circulating tumor cells, liquid biopsies can accurately diagnose cancer before the tumor becomes visible.
Segmentation by Application
- Cancer
- Non-cancer
INSIGHTS BY BIOMARKER TYPE
The cfDNA & ctDNA biomarker type segment dominated the global liquid biopsy market, accounting for over 41% in 2022. Cell-free DNA (cfDNA) is a rapidly developing technology in liquid biopsy that has opened a new field of cancer diagnosis and patient management. It involves DNA extraction from a sample of circulating blood, which can then be analyzed for the presence of genetic mutations. These mutations are associated with cancer development and can provide a detailed picture of a patient's disease.
Segmentation by Biomarker Type
- Cell-free DNA (cfDNA) & Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs)
INSIGHTS BY TECHNOLOGY
The next-generation sequencing (NGS) technology segment dominated the global liquid biopsy market in 2022. Liquid biopsy is a revolutionary technique that has transformed the field of cancer diagnosis and treatment. Liquid biopsy has greatly advanced the study of cancer genomics using NGS. NGS is a powerful and cost-effective technology that enables the rapid sequencing of large amounts of genetic material. NGS sequences the sample's genetic material and identifies any cancer-related mutations. Through this process, researchers can detect cancer at earlier stages and determine the type and aggressiveness of the cancer. The data generated from NGS can be used to develop targeted therapies and improve patient outcomes.
Segmentation by Technology
- Next-generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
INSIGHTS BY END-USER
The hospital end-user segment accounted for the largest global liquid biopsy market share. As medical technology advances, liquid biopsy in hospitals is becoming more commonplace. Liquid biopsy is a relatively new technology that utilizes a patient's blood, urine, or other body fluids to detect cancer cells or biomarkers. This method offers an alternative to traditional tissue biopsies, which are invasive, painful, and expensive. By detecting cancer cells or markers from a simple blood or urine sample, liquid biopsy can provide non-invasive, cost-effective, and timely diagnostic information. The use of liquid biopsy in hospitals is increasing due to its versatility and convenience. It can detect various cancers, including breast, colorectal, lung, prostate, and ovarian. It can also detect cancer at earlier stages, providing earlier diagnosis and treatment. Using liquid biopsy for cancer detection is also beneficial because it can monitor real-time response to treatment, such as chemotherapy or immunotherapy.
Segmentation by End-user
- Hospitals
- Diagnostic Laboratories
- Others
GEOGRAPHICAL ANALYSIS
North America dominated the global liquid biopsy market share, accounting for over 48% in 2022. The increasing demand for liquid biopsy technology in North America comes in the face of growing cancer rates across the U.S. and Canada, as well as an increased awareness of the early diagnostic benefits of this technology. Liquid biopsies can provide detailed information on the presence of the disease, its type, and its progression in the body much earlier than traditional methods and procedures.
Segmentation by Geography
- North America
o The U.S.
o Canada
- Europe
o Germany
o France
o The U.K.
o Italy
o Spain
- APAC
o China
o Japan
o India
o South Korea
o Australia
- Latin America
o Brazil
o Mexico
o Argentina
- Middle East & Africa
o Turkey
o Saudi Arabia
o South Africa
COMPETITIVE LANDSCAPE
Competing in the global liquid biopsy market demands robust clinical validation and regulatory approvals. Companies that successfully navigate regulatory pathways, obtain approvals from health authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and provide solid clinical evidence gain a competitive advantage. Validated assays with regulatory endorsements instill confidence in healthcare professionals and contribute to industry penetration. Continuous advancements in sequencing technologies, digital PCR, and other analytical platforms have improved the sensitivity and specificity of liquid biopsy tests. These advancements enhance the ability to detect rare mutations and monitor tumor heterogeneity.
Key Company Profiles
- Agilent Technologies
- F. Hoffmann-La Roche
- Guardant Health
- Illumina
- QIAGEN
- Thermo Fisher Scientific
Other Prominent Vendors
- Agena Bioscience
- ANGLE
- Biocept
- Biodesix
- Biolidics
- Bio-Rad Laboratories
- BIOVIEW
- Caris Life Sciences
- Epigenomics
- Freenome Holdings
- Invitae Corporation
- Laboratory Corporation of America
- Lucence Health
- LungLife AI
- mdxhealth
- Menarini Silicon Biosystems
- Natera
- NeoGenomics Laboratories
- Sysmex Corporation
- TEMPUS
KEY QUESTIONS ANSWERED:
1. How big is the liquid biopsy market?
2. What is the growth rate of the global liquid biopsy market?
3. Which region dominates the global liquid biopsy market share?
4. What are the significant trends in the liquid biopsy industry?
5. Who are the key players in the global liquid biopsy market?
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY PRODUCT
4.3.2 MARKET SEGMENTATION BY SAMPLE TYPE
4.3.3 MARKET SEGMENTATION BY APPLICATION
4.3.4 MARKET SEGMENTATION BY BIOMARKER TYPE
4.3.5 MARKET SEGMENTATION BY TECHNOLOGY
4.3.6 MARKET SEGMENTATION BY END-USER
4.3.7 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 PREMIUM INSIGHTS
6.1 OVERVIEW
6.1.1 GEOGRAPHY INSIGHTS
6.1.2 PRODUCT INSIGHTS
6.1.3 SAMPLE TYPE
6.1.4 APPLICATION INSIGHTS
6.1.5 BIOMARKER TYPE
6.1.6 TECHNOLOGY INSIGHTS
6.1.7 END-USER INSIGHTS
7 MARKET AT A GLANCE
8 INTRODUCTION
8.1 OVERVIEW
9 MARKET OPPORTUNITIES & TRENDS
9.1 ROLE OF LIQUID BIOPSY AS A COMPANION DIAGNOSTICS
9.2 GOVERNMENT INITIATIVES & FUNDING FOR LIQUID BIOPSY
9.3 USE OF LIQUID BIOPSY IN NON-CANCER APPLICATIONS
9.4 NEW PRODUCT LAUNCHES
10 MARKET GROWTH ENABLERS
10.1 HIGH GLOBAL CANCER PREVALENCE
10.2 PATIENT PREFERENCE FOR NON-INVASIVE DIAGNOSIS & MONITORING
10.3 TECHNOLOGICAL ADVANCES IN CLINICAL APPLICATIONS OF LIQUID BIOPSY
10.4 TRANSFORMATION OF PRECISION CANCER CARE
11 MARKET RESTRAINTS
11.1 HIGH COST OF LIQUID BIOPSY COMPARED WITH TRADITIONAL BIOPSY
11.2 ACCEPTANCE & AWARENESS OF LIQUID BIOPSIES IN LMICS
11.3 LACK OF SKILLED WORKFORCE
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET BY GEOGRAPHY
12.3.2 MARKET BY PRODUCT
12.3.3 MARKET BY SAMPLE TYPE
12.3.4 MARKET BY APPLICATION
12.3.5 MARKET BY BIOMARKER TYPE
12.3.6 MARKET BY TECHNOLOGY
12.3.7 MARKET BY END-USER
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 PRODUCT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 KITS & REAGENTS
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 KITS & REAGENTS SEGMENT BY GEOGRAPHY
13.4 INSTRUMENTS & PLATFORMS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 INSTRUMENTS & PLATFORMS SEGMENT BY GEOGRAPHY
14 SAMPLE TYPE
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 BLOOD
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 BLOOD SEGMENT BY GEOGRAPHY
14.4 OTHER SAMPLES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 OTHER SAMPLES SEGMENT BY GEOGRAPHY
15 APPLICATION
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 CANCER
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 CANCER SEGMENT BY GEOGRAPHY
15.4 NON-CANCER
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 NON-CANCER SEGMENT BY GEOGRAPHY
16 BIOMARKER TYPE
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 CFDNA & CTDNA
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 CFDNA & CTDNA SEGMENT BY GEOGRAPHY
16.4 CTCS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 CTCS SEGMENT BY GEOGRAPHY
16.5 EXTRACELLULAR VESICLES
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.5.3 EXTRACELLULAR VESICLES SEGMENT BY GEOGRAPHY
17 TECHNOLOGY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 NGS
17.3.1 MARKET OVERVIEW
17.3.2 MARKET SIZE & FORECAST
17.3.3 NGS SEGMENT BY GEOGRAPHY
17.4 PCR
17.4.1 MARKET OVERVIEW
17.4.2 MARKET SIZE & FORECAST
17.4.3 PCR SEGMENT BY GEOGRAPHY
18 END-USER
18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 MARKET OVERVIEW
18.3 HOSPITALS
18.3.1 MARKET OVERVIEW
18.3.2 MARKET SIZE & FORECAST
18.3.3 HOSPITALS SEGMENT BY GEOGRAPHY
18.4 DIAGNOSTIC LABORATORIES
18.4.1 MARKET OVERVIEW
18.4.2 MARKET SIZE & FORECAST
18.4.3 DIAGNOSTIC LABORATORIES SEGMENT BY GEOGRAPHY
18.5 OTHER END-USERS
18.5.1 MARKET OVERVIEW
18.5.2 MARKET SIZE & FORECAST
18.5.3 OTHERS SEGMENT BY GEOGRAPHY
19 GEOGRAPHY
19.1 MARKET SNAPSHOT & GROWTH ENGINE
19.2 GEOGRAPHIC OVERVIEW
20 NORTH AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 NORTH AMERICA MARKET BY PRODUCT
20.2.2 NORTH AMERICA MARKET BY SAMPLE TYPE
20.2.3 NORTH AMERICA MARKET BY APPLICATION
20.2.4 NORTH AMERICA MARKET BY BIOMARKER TYPE
20.2.5 NORTH AMERICA MARKET BY TECHNOLOGY
20.2.6 NORTH AMERICA MARKET BY END-USER
20.3 KEY COUNTRIES
20.3.1 US: MARKET SIZE & FORECAST
20.3.2 CANADA: MARKET SIZE & FORECAST
21 EUROPE
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 EUROPE MARKET BY PRODUCT
21.2.2 EUROPE MARKET BY SAMPLE TYPE
21.2.3 EUROPE MARKET BY APPLICATION
21.2.4 EUROPE MARKET BY BIOMARKER TYPE
21.2.5 EUROPE MARKET BY TECHNOLOGY
21.2.6 EUROPE MARKET BY END-USER
21.3 KEY COUNTRIES
21.3.1 GERMANY: MARKET SIZE & FORECAST
21.3.2 FRANCE: MARKET SIZE & FORECAST
21.3.3 UK: MARKET SIZE & FORECAST
21.3.4 ITALY: MARKET SIZE & FORECAST
21.3.5 SPAIN: MARKET SIZE & FORECAST
22 APAC
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.2.1 APAC MARKET BY PRODUCT
22.2.2 APAC MARKET BY SAMPLE TYPE
22.2.3 APAC MARKET BY APPLICATION
22.2.4 APAC MARKET BY BIOMARKER TYPE
22.2.5 APAC MARKET BY TECHNOLOGY
22.2.6 APAC MARKET BY END-USER
22.3 KEY COUNTRIES
22.3.1 CHINA: MARKET SIZE & FORECAST
22.3.2 JAPAN: MARKET SIZE & FORECAST
22.3.3 INDIA: MARKET SIZE & FORECAST
22.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
22.3.5 AUSTRALIA: MARKET SIZE & FORECAST
23 LATIN AMERICA
23.1 MARKET OVERVIEW
23.2 MARKET SIZE & FORECAST
23.2.1 LATIN AMERICA MARKET BY PRODUCT
23.2.2 LATIN AMERICA MARKET BY SAMPLE TYPE
23.2.3 LATIN AMERICA MARKET BY APPLICATION
23.2.4 LATIN AMERICA MARKET BY BIOMARKER TYPE
23.2.5 LATIN AMERICA MARKET BY TECHNOLOGY
23.2.6 LATIN AMERICA MARKET BY END-USER
23.3 KEY COUNTRIES
23.3.1 BRAZIL: MARKET SIZE & FORECAST
23.3.2 MEXICO: MARKET SIZE & FORECAST
23.3.3 ARGENTINA: MARKET SIZE & FORECAST
24 MIDDLE EAST & AFRICA
24.1 MARKET OVERVIEW
24.2 MARKET SIZE & FORECAST
24.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT
24.2.2 MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE
24.2.3 MIDDLE EAST & AFRICA MARKET BY APPLICATION
24.2.4 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
24.2.5 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
24.2.6 MIDDLE EAST & AFRICA MARKET BY END-USER
24.3 KEY COUNTRIES
24.3.1 TURKEY: MARKET SIZE & FORECAST
24.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
24.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST
25 COMPETITIVE LANDSCAPE
25.1 COMPETITION OVERVIEW
25.2 MARKET SHARE ANALYSIS
25.2.1 AGILENT TECHNOLOGIES
25.2.2 F. HOFFMANN-LA ROCHE
25.2.3 GUARDANT HEALTH
25.2.4 ILLUMINA
25.2.5 QIAGEN
25.2.6 THERMO FISHER SCIENTIFIC
26 KEY COMPANY PROFILES
26.1 AGILENT TECHNOLOGIES
26.1.1 BUSINESS OVERVIEW
26.1.2 PRODUCT OFFERINGS
26.1.3 KEY STRATEGIES
26.1.4 KEY STRENGTHS
26.1.5 KEY OPPORTUNITIES
26.2 F. HOFFMANN-LA ROCHE
26.2.1 BUSINESS OVERVIEW
26.2.2 PRODUCT OFFERINGS
26.2.3 KEY STRATEGIES
26.2.4 KEY STRENGTHS
26.2.5 KEY OPPORTUNITIES
26.3 GUARDANT HEALTH
26.3.1 BUSINESS OVERVIEW
26.3.2 PRODUCT OFFERINGS
26.3.3 KEY STRATEGIES
26.3.4 KEY STRENGTHS
26.3.5 KEY OPPORTUNITIES
26.4 ILLUMINA
26.4.1 BUSINESS OVERVIEW
26.4.2 PRODUCT OFFERINGS
26.4.3 KEY STRATEGIES
26.4.4 KEY STRENGTHS
26.4.5 KEY OPPORTUNITIES
26.5 QIAGEN
26.5.1 BUSINESS OVERVIEW
26.5.2 PRODUCT OFFERINGS
26.5.3 KEY STRATEGIES
26.5.4 KEY STRENGTHS
26.5.5 KEY OPPORTUNITIES
26.6 THERMO FISHER SCIENTIFIC
26.6.1 BUSINESS OVERVIEW
26.6.2 PRODUCT OFFERINGS
26.6.3 KEY STRATEGIES
26.6.4 KEY STRENGTHS
26.6.5 KEY OPPORTUNITIES
27 OTHER PROMINENT VENDORS
27.1 AGENA BIOSCIENCE
27.1.1 BUSINESS OVERVIEW
27.1.2 PRODUCT OFFERINGS
27.2 ANGLE
27.2.1 BUSINESS OVERVIEW
27.2.2 PRODUCT OFFERINGS
27.3 BIOCEPT
27.3.1 BUSINESS OVERVIEW
27.3.2 PRODUCT OFFERINGS
27.4 BIODESIX
27.4.1 BUSINESS OVERVIEW
27.4.2 PRODUCT OFFERINGS
27.5 BIOLIDICS
27.5.1 BUSINESS OVERVIEW
27.5.2 PRODUCT OFFERINGS
27.6 BIO-RAD LABORATORIES
27.6.1 BUSINESS OVERVIEW
27.6.2 PRODUCT OFFERINGS
27.7 BIOVIEW
27.7.1 BUSINESS OVERVIEW
27.7.2 PRODUCT OFFERINGS
27.8 CARIS LIFE SCIENCES
27.8.1 BUSINESS OVERVIEW
27.8.2 PRODUCT OFFERINGS
27.9 EPIGENOMICS
27.9.1 BUSINESS OVERVIEW
27.9.2 PRODUCT OFFERINGS
27.10 FREENOME HOLDINGS
27.10.1 BUSINESS OVERVIEW
27.10.2 PRODUCT OFFERINGS
27.11 INVITAE CORPORATION
27.11.1 BUSINESS OVERVIEW
27.11.2 PRODUCT OFFERINGS
27.12 LABORATORY CORPORATION OF AMERICA
27.12.1 BUSINESS OVERVIEW
27.12.2 PRODUCT OFFERINGS
27.13 LUCENCE HEALTH
27.13.1 BUSINESS OVERVIEW
27.13.2 PRODUCT OFFERINGS
27.14 LUNGLIFE AI
27.14.1 BUSINESS OVERVIEW
27.14.2 PRODUCT OFFERINGS
27.15 MDXHEALTH
27.15.1 BUSINESS OVERVIEW
27.15.2 PRODUCT OFFERINGS
27.16 MENARINI SILICON BIOSYSTEMS
27.16.1 BUSINESS OVERVIEW
27.16.2 PRODUCT OFFERINGS
27.17 NATERA
27.17.1 BUSINESS OVERVIEW
27.17.2 PRODUCT OFFERINGS
27.18 NEOGENOMICS LABORATORIES
27.18.1 BUSINESS OVERVIEW
27.18.2 PRODUCT OFFERINGS
27.19 SYSMEX CORPORATION
27.19.1 BUSINESS OVERVIEW
27.19.2 PRODUCT OFFERINGS
27.20 TEMPUS
27.20.1 BUSINESS OVERVIEW
27.20.2 PRODUCT OFFERINGS
28 REPORT SUMMARY
28.1 KEY TAKEAWAYS
28.2 STRATEGIC RECOMMENDATIONS
29 QUANTITATIVE SUMMARY
29.1 MARKET BY PRODUCT
29.1.1 NORTH AMERICA MARKET BY PRODUCT
29.1.2 EUROPE MARKET BY PRODUCT
29.1.3 APAC MARKET BY PRODUCT
29.1.4 LATIN AMERICA MARKET BY PRODUCT
29.1.5 MIDDLE EAST & AFRICA MARKET BY PRODUCT
29.2 MARKET BY SAMPLE TYPE
29.2.1 NORTH AMERICA MARKET BY SAMPLE TYPE
29.2.2 EUROPE MARKET BY SAMPLE TYPE
29.2.3 APAC MARKET BY SAMPLE TYPE
29.2.4 LATIN AMERICA MARKET BY SAMPLE TYPE
29.2.5 MIDDLE EAST & AFRICA MARKET BY SAMPLE TYPE
29.3 MARKET BY APPLICATION
29.3.1 NORTH AMERICA MARKET BY APPLICATION
29.3.2 EUROPE MARKET BY APPLICATION
29.3.3 APAC MARKET BY APPLICATION
29.3.4 LATIN AMERICA MARKET BY APPLICATION
29.3.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
29.4 MARKET BY BIOMARKER TYPE
29.4.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
29.4.2 EUROPE MARKET BY BIOMARKER TYPE
29.4.3 APAC MARKET BY BIOMARKER TYPE
29.4.4 LATIN AMERICA MARKET BY BIOMARKER TYPE
29.4.5 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
29.5 MARKET BY TECHNOLOGY
29.5.1 NORTH AMERICA MARKET BY TECHNOLOGY
29.5.2 EUROPE MARKET BY TECHNOLOGY
29.5.3 APAC MARKET BY TECHNOLOGY
29.5.4 LATIN AMERICA MARKET BY TECHNOLOGY
29.5.5 MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
29.6 MARKET BY END-USER
29.6.1 NORTH AMERICA MARKET BY END-USER
29.6.2 EUROPE MARKET BY END-USER
29.6.3 APAC MARKET BY END-USER
29.6.4 LATIN AMERICA MARKET BY END-USER
29.6.5 MIDDLE EAST & AFRICA MARKET BY END-USER
29.7 MARKET BY GEOGRAPHY
29.7.1 KITS & REAGENTS SEGMENT BY GEOGRAPHY
29.7.2 INSTRUMENTS & PLATFORMS SEGMENT BY GEOGRAPHY
29.7.3 BLOOD SEGMENT BY GEOGRAPHY
29.7.4 OTHER SAMPLES SEGMENT BY GEOGRAPHY
29.7.5 CANCER SEGMENT BY GEOGRAPHY
29.7.6 NON-CANCER SEGMENT BY GEOGRAPHY
29.7.7 CFDNA & CTDNA SEGMENT BY GEOGRAPHY
29.7.8 CTCS SEGMENT BY GEOGRAPHY
29.7.9 EXTRACELLULAR VESICLES SEGMENT BY GEOGRAPHY
29.7.10 NGS SEGMENT BY GEOGRAPHY
29.7.11 PCR SEGMENT BY GEOGRAPHY
29.7.12 HOSPITALS SEGMENT BY GEOGRAPHY
29.7.13 DIAGNOSTIC LABORATORIES SEGMENT BY GEOGRAPHY
29.7.14 OTHER END-USERS SEGMENT BY GEOGRAPHY
30 APPENDIX
30.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL LIQUID BIOPSY MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 4 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 5 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 6 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 7 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 8 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 9 GLOBAL LIQUID BIOPSY MARKET BY END-USER: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 10 IMPACT OF ROLE OF LIQUID BIOPSY AS A COMPANION DIAGNOSTICS
EXHIBIT 11 IMPACT OF GOVERNMENT INITIATIVES & FUNDING FOR LIQUID BIOPSY
EXHIBIT 12 IMPACT OF USE OF LIQUID BIOPSY IN NON-CANCER APPLICATIONS
EXHIBIT 13 IMPACT OF NEW PRODUCT LAUNCHES
EXHIBIT 14 IMPACT OF HIGH GLOBAL CANCER PREVALENCE
EXHIBIT 15 IMPACT OF PATIENT PREFERENCE FOR NON-INVASIVE DIAGNOSIS & MONITORING
EXHIBIT 16 IMPACT OF TECHNOLOGICAL ADVANCES IN CLINICAL APPLICATIONS OF LIQUID BIOPSY
EXHIBIT 17 IMPACT OF TRANSFORMATION OF PRECISION CANCER CARE
EXHIBIT 18 IMPACT OF HIGH COST OF LIQUID BIOPSY COMPARED WITH TRADITIONAL BIOPSY
EXHIBIT 19 IMPACT OF ACCEPTANCE & AWARENESS OF LIQUID BIOPSIES IN LMICS
EXHIBIT 20 IMPACT OF LACK OF SKILLED WORKFORCE
EXHIBIT 21 GLOBAL LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 22 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 23 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 24 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 25 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 26 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 27 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 28 GLOBAL LIQUID BIOPSY MARKET BY END-USER: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 29 FIVE FORCES ANALYSIS 2022
EXHIBIT 30 INCREMENTAL GROWTH BY PRODUCT 2022 & 2028
EXHIBIT 31 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 32 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: ABSOLUTE GROWTH (%)
EXHIBIT 33 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 35 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 36 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 37 INCREMENTAL GROWTH BY SAMPLE TYPE 2022 & 2028
EXHIBIT 38 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 39 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 40 GLOBAL BLOOD LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL BLOOD LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 42 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 44 INCREMENTAL GROWTH BY APPLICATION 2022 & 2028
EXHIBIT 45 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 46 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: ABSOLUTE GROWTH (%)
EXHIBIT 47 GLOBAL CANCER LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL CANCER LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 49 GLOBAL NON-CANCER LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL NON-CANCER LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 51 INCREMENTAL GROWTH BY BIOMARKER TYPE 2022 & 2028
EXHIBIT 52 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 53 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 54 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 56 GLOBAL CTCS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 GLOBAL CTCS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 58 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY TECHNOLOGY 2022 & 2028
EXHIBIT 61 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 62 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: ABSOLUTE GROWTH (%)
EXHIBIT 63 GLOBAL NGS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 GLOBAL NGS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 65 GLOBAL PCR LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL PCR LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 67 INCREMENTAL GROWTH BY END-USER 2022 & 2028
EXHIBIT 68 GLOBAL LIQUID BIOPSY MARKET BY END-USER: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 69 GLOBAL LIQUID BIOPSY MARKET BY END-USER: ABSOLUTE GROWTH (%)
EXHIBIT 70 GLOBAL HOSPITALS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 GLOBAL HOSPITALS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 72 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 74 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 75 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 76 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028
EXHIBIT 77 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 78 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
EXHIBIT 79 NORTH AMERICA LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 80 NORTH AMERICA LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 NORTH AMERICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 82 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028
EXHIBIT 83 US PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 84 US LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 85 CANADA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 86 EUROPE LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 87 EUROPE LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 88 EUROPE LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 89 INCREMENTAL GROWTH IN EUROPE 2022 & 2028
EXHIBIT 90 GERMANY PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 91 GERMANY LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 92 FRANCE PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 93 FRANCE LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 94 UK PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 95 UK LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 96 ITALY PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 97 ITALY LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 98 SPAIN LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 99 APAC LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 100 APAC LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 101 APAC LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 102 INCREMENTAL GROWTH IN APAC 2022 & 2028
EXHIBIT 103 CHINA PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 104 CHINA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 105 JAPAN PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 106 JAPAN LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 107 INDIA PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 108 INDIA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 109 SOUTH KOREA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 110 AUSTRALIA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 111 LATIN AMERICA LIQUID BIOPSY MARKET 2022-2028: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 112 LATIN AMERICA LIQUID BIOPSY MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 113 LATIN AMERICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 114 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028
EXHIBIT 115 BRAZIL PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 116 BRAZIL LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 117 MEXICO PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 118 MEXICO LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 119 ARGENTINA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 120 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 121 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 122 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 123 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028
EXHIBIT 124 TURKEY LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 125 SAUDI ARABIA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 126 SOUTH AFRICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 127 VENDORS OFFERING LIQUID BIOPSY PRODUCTS: MARKET DOMINANCE ANALYSIS
EXHIBIT 128 VENDORS OFFERING COMMERCIAL LIQUID BIOPSY PRODUCTS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 129 AGILENT TECHNOLOGIES: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 130 AGILENT TECHNOLOGIES: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 131 AGILENT TECHNOLOGIES: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 132 AGILENT TECHNOLOGIES: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 133 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 134 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 135 F. HOFFMANN-LA ROCHE: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 136 GUARDANT HEALTH: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 137 GUARDANT HEALTH: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 138 GUARDANT HEALTH: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 139 ILLUMINA: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 140 ILLUMINA: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 141 ILLUMINA: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 142 ILLUMINA: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 143 QIAGEN: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 144 QIAGEN: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 145 QIAGEN: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 146 QIAGEN: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 147 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 148 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 149 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 150 THERMO FISHER SCIENTIFIC: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL LIQUID BIOPSY MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 4 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 5 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 6 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 7 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 8 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 9 GLOBAL LIQUID BIOPSY MARKET BY END-USER: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 10 IMPACT OF ROLE OF LIQUID BIOPSY AS A COMPANION DIAGNOSTICS
EXHIBIT 11 IMPACT OF GOVERNMENT INITIATIVES & FUNDING FOR LIQUID BIOPSY
EXHIBIT 12 IMPACT OF USE OF LIQUID BIOPSY IN NON-CANCER APPLICATIONS
EXHIBIT 13 IMPACT OF NEW PRODUCT LAUNCHES
EXHIBIT 14 IMPACT OF HIGH GLOBAL CANCER PREVALENCE
EXHIBIT 15 IMPACT OF PATIENT PREFERENCE FOR NON-INVASIVE DIAGNOSIS & MONITORING
EXHIBIT 16 IMPACT OF TECHNOLOGICAL ADVANCES IN CLINICAL APPLICATIONS OF LIQUID BIOPSY
EXHIBIT 17 IMPACT OF TRANSFORMATION OF PRECISION CANCER CARE
EXHIBIT 18 IMPACT OF HIGH COST OF LIQUID BIOPSY COMPARED WITH TRADITIONAL BIOPSY
EXHIBIT 19 IMPACT OF ACCEPTANCE & AWARENESS OF LIQUID BIOPSIES IN LMICS
EXHIBIT 20 IMPACT OF LACK OF SKILLED WORKFORCE
EXHIBIT 21 GLOBAL LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 22 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 23 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 24 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 25 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 26 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 27 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 28 GLOBAL LIQUID BIOPSY MARKET BY END-USER: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 29 FIVE FORCES ANALYSIS 2022
EXHIBIT 30 INCREMENTAL GROWTH BY PRODUCT 2022 & 2028
EXHIBIT 31 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 32 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT: ABSOLUTE GROWTH (%)
EXHIBIT 33 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL KITS & REAGENTS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 35 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 36 GLOBAL INSTRUMENTS & PLATFORMS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 37 INCREMENTAL GROWTH BY SAMPLE TYPE 2022 & 2028
EXHIBIT 38 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 39 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 40 GLOBAL BLOOD LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL BLOOD LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 42 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL OTHER SAMPLES LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 44 INCREMENTAL GROWTH BY APPLICATION 2022 & 2028
EXHIBIT 45 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 46 GLOBAL LIQUID BIOPSY MARKET BY APPLICATION: ABSOLUTE GROWTH (%)
EXHIBIT 47 GLOBAL CANCER LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL CANCER LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 49 GLOBAL NON-CANCER LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL NON-CANCER LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 51 INCREMENTAL GROWTH BY BIOMARKER TYPE 2022 & 2028
EXHIBIT 52 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 53 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 54 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL CFDNA & CTDNA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 56 GLOBAL CTCS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 57 GLOBAL CTCS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 58 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL EXTRACELLULAR VESICLES LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY TECHNOLOGY 2022 & 2028
EXHIBIT 61 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 62 GLOBAL LIQUID BIOPSY MARKET BY TECHNOLOGY: ABSOLUTE GROWTH (%)
EXHIBIT 63 GLOBAL NGS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 GLOBAL NGS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 65 GLOBAL PCR LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL PCR LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 67 INCREMENTAL GROWTH BY END-USER 2022 & 2028
EXHIBIT 68 GLOBAL LIQUID BIOPSY MARKET BY END-USER: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 69 GLOBAL LIQUID BIOPSY MARKET BY END-USER: ABSOLUTE GROWTH (%)
EXHIBIT 70 GLOBAL HOSPITALS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 GLOBAL HOSPITALS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 72 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 GLOBAL DIAGNOSTIC LABORATORIES LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 74 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 75 GLOBAL OTHER END-USERS LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 76 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028
EXHIBIT 77 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 78 GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
EXHIBIT 79 NORTH AMERICA LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 80 NORTH AMERICA LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 NORTH AMERICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 82 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028
EXHIBIT 83 US PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 84 US LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 85 CANADA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 86 EUROPE LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 87 EUROPE LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 88 EUROPE LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 89 INCREMENTAL GROWTH IN EUROPE 2022 & 2028
EXHIBIT 90 GERMANY PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 91 GERMANY LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 92 FRANCE PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 93 FRANCE LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 94 UK PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 95 UK LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 96 ITALY PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 97 ITALY LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 98 SPAIN LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 99 APAC LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 100 APAC LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 101 APAC LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 102 INCREMENTAL GROWTH IN APAC 2022 & 2028
EXHIBIT 103 CHINA PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 104 CHINA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 105 JAPAN PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 106 JAPAN LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 107 INDIA PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 108 INDIA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 109 SOUTH KOREA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 110 AUSTRALIA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 111 LATIN AMERICA LIQUID BIOPSY MARKET 2022-2028: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 112 LATIN AMERICA LIQUID BIOPSY MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 113 LATIN AMERICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 114 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028
EXHIBIT 115 BRAZIL PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 116 BRAZIL LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 117 MEXICO PREVALENCE OF CANCER (NUMBER OF NEW CASES) (2020)
EXHIBIT 118 MEXICO LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 119 ARGENTINA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 120 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 121 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2022-2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 122 MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 123 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028
EXHIBIT 124 TURKEY LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 125 SAUDI ARABIA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 126 SOUTH AFRICA LIQUID BIOPSY MARKET 2022-2028 ($ BILLION)
EXHIBIT 127 VENDORS OFFERING LIQUID BIOPSY PRODUCTS: MARKET DOMINANCE ANALYSIS
EXHIBIT 128 VENDORS OFFERING COMMERCIAL LIQUID BIOPSY PRODUCTS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 129 AGILENT TECHNOLOGIES: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 130 AGILENT TECHNOLOGIES: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 131 AGILENT TECHNOLOGIES: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 132 AGILENT TECHNOLOGIES: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 133 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 134 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 135 F. HOFFMANN-LA ROCHE: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 136 GUARDANT HEALTH: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 137 GUARDANT HEALTH: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 138 GUARDANT HEALTH: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 139 ILLUMINA: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 140 ILLUMINA: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 141 ILLUMINA: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 142 ILLUMINA: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 143 QIAGEN: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 144 QIAGEN: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 145 QIAGEN: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 146 QIAGEN: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 147 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2020-2022 ($ BILLION)
EXHIBIT 148 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2020-2022 ($ BILLION)
EXHIBIT 149 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 150 THERMO FISHER SCIENTIFIC: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security